BBK Worldwide Builds on Tablet Function in Latest Version of Study eBinder
BBK Worldwide announced the latest version its Study eBinder
BBK Worldwide announced the latest version its Study eBinder, which addresses more customization for its tablet that study teams use. Version 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff in its proprietary patient recruitment portal, TrialCentralNet (TCN®). The new version also is fully customizable for the sponsor's brand and content.
You can read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
